Skip to Main Content

Hello, everyone, and how are you this fine, sunny morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made it this far, which is a likely sign of surviving another few days. And of course, no prescription is required, which is a good thing. Our choice today is pumpkin spice, a year-round treat. And while you drink up, you can peruse some of the tidbits we have assembled to help you start the day. Hope you conquer the world and, as always, do keep in touch. …

Amid rising concern over antimicrobial resistance, the U.K. has taken a major step toward becoming the first country to launch an experimental payment model for antibiotics, a move designed to usher in a new era of drug development and reimbursement, STAT writes. The government completed a long-awaited cost-effectiveness review of two new antibiotics as part of a pilot program that would pay for the medicines using a so-called subscription model. The idea is to pay companies upfront fees based on the estimated value of benefits to patients and the country’s National Health Service, rather than payments based on volumes used.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment